EUVIMEDEUVIMED entdecken
Open Access

The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells

Trini A Ochoa iD, Amy Rossi iD, E Steve Woodle iD, David Hildeman iD, David Allman

The Journal of Immunology · 2024

DOI: 10.4049/jimmunol.2300212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Trini A Ochoa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Proteasome Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The proteasome inhibitor bortezomib (BTZ) is proposed to deplete activated B cells and plasma cells. However, a complete picture of the mechanisms underlying BTZ-induced apoptosis in B lineage cells remains to be established. In this study, using a direct in vitro approach, we show that deletion of the tumor suppressor and cell cycle regulator p53 rescues recently activated mouse B cells from BTZ-induced apoptosis. Furthermore, BTZ treatment elevated intracellular p53 levels, and p53 deletion constrained apoptosis, as recently stimulated cells first transitioned from the G1 to S phase of the cell cycle. Moreover, combined inhibition of the p53-associated cell cycle regulators and E3 ligases MDM2 and anaphase-promoting complex/cyclosome induced cell death in postdivision B cells. Our results reveal that efficient cell cycle progression of activated B cells requires proteasome-driven inhibition of p53. Consequently, BTZ-mediated interference of proteostasis unleashes a p53-dependent cell cycle–associated death mechanism in recently activated B cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteasome InhibitorsAntineoplastic AgentsAnimalsMiceBortezomibTumor Suppressor Protein p53Cell Line, TumorProteasome Endopeptidase ComplexApoptosis

Substanzen

BortezomibProteasome InhibitorsAntineoplastic AgentsTumor Suppressor Protein p53Proteasome Endopeptidase Complex

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Division of Transplant Surgery, University of Cincinnati College of Medicine, Cincinnati, OH.

ORCID-Profile: Trini A Ochoa, Amy Rossi, E Steve Woodle, David Hildeman

Förderung

  • NIAID NIH HHS
  • HHS | National Institutes of Health

Zitieren

APA

Ochoa, T. A., Rossi, A., Woodle, E. S., Hildeman, D., & Allman, D. (2024). The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300212

Vancouver

Ochoa TA, Rossi A, Woodle ES, Hildeman D, Allman D. The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2300212

BibTeX
@article{Ochoa2024,
  author = {Ochoa, Trini A and Rossi, Amy and Woodle, E Steve and Hildeman, David and Allman, David},
  title = {The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells},
  journal = {The Journal of Immunology},
  year = {2024},
  doi = {10.4049/jimmunol.2300212}
}
Kostenlos starten →